Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

24,266 signal articles · 41 in last 24h · 115,320 total before filter · latest 1h ago
41last 24h
1799last 7d
300● bullish (7d)
170● bearish (7d)
205publishers
AllMacro320Earnings844M&A103Regulatory25Product16Analyst25
✕ clear all filtersticker: LLYSentiment:bullishneutralbearishshow all (incl. clickbait)
Novo Nordisk slightly raises outlook as first-quarter profit beats forecast
Reuters101d agobullish
Novo Nordisk slightly raises outlook as first-quarter profit beats forecast

COPENHAGEN, May 6 () - Novo Nordisk, the maker of weight-loss drug Wegovy, on Wednesday reported first-quarter revenue and adjusted operating profit above expectations and said its outlook ‌for the year was slightly improved. The Danish drugmaker is banking on demand for ‌its new weight-loss pill as competition with U.

Schrodinger Q1 Earnings Call Highlights
MarketBeat102d agoneutral
Schrodinger Q1 Earnings Call Highlights

Schrodinger (NASDAQ:SDGR) reported first-quarter 2026 results and highlighted progress in its transition to hosted software licensing, growth in annual contract value (ACV), and recent business development activity tied to its drug discovery collaborations. First-quarter metrics and hosted transiti

BofA sees more upside in Eli Lilly stock
TheStreet105d agoneutral
BofA sees more upside in Eli Lilly stock

Eli Lilly’s first-quarter report gave Wall Street another reason to stay optimistic about one of the market’s biggest pharmaceutical winners, even as analysts continue to weigh how much growth is already priced into the stock. Bank of America reiterated its Buy rating on Eli Lilly and set a $1,133 ...

Eli Lilly and Company Q1 Earnings Call Highlights
MarketBeat106d agoneutral
Eli Lilly and Company Q1 Earnings Call Highlights

Eli Lilly and Company (NYSE:LLY) executives said the drugmaker started 2026 with “a strong start,” pointing to sharp first-quarter revenue growth, continued demand for its incretin medicines, a newly approved oral obesity therapy, and a slate of pipeline and business development milestones. Founday